Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Feb 23 2016

Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with Baylor Miraca Genetics Laboratories (BMGL), a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.

According to Cynthia Sheridan, Diversigen President, "Our pharmaceutical customers have expressed an interest in correlating microbiome data with specific host genetic traits to better understand the host-microbiome relationship as a factor in disease and in the search for more effective therapies. This partnership with BMGL will allow us to provide broader services resulting in deeper insights into human health and disease."

"As we continue to transition from an academically-centered genetic laboratory to a commercial organization focused on advancing patient health, access to the expert microbiome resources of the Diversigen team makes perfect sense," said Gary Huff, President and CEO of Baylor Miraca.

SOURCE Diversigen, Inc.